Results 101 to 110 of about 326,443 (336)

Rapid Microfluidic Drug Sensitivity Testing Within 5 Days Using Minimal Clinical Tumor Samples

open access: yesAdvanced Science, EarlyView.
This study develops the air‐punched fabrication approach for nanoliter‐scale microcavity arrays with ultra‐smooth microcavity surfaces, with which rapid formation and 3D culture of tumor cell spheroids from small numbers of cell samples, as well as high‐throughput drug sensitivity testing can be achieved within 5 days.
Yi‐Xue Chen   +11 more
wiley   +1 more source

Epidemiological and pathological characteristics of postsurgical cases of invasive breast cancer among ethnicities of Iran in 2018: A single center cross-sectional study [PDF]

open access: yesArchive of Oncology, 2020
Background: Present study aimed to investigate immunohistochemical parameters in post-surgical cases of invasive breast cancer. Methods: In this single center cross-sectional study we investigated ethnicity, familial history, type of cancer, stage of ...
Sayad Soheila   +4 more
doaj  

Biophysical evidence for intrinsic disorder in the C-terminal tails of the epidermal growth factor receptor (EGFR) and HER3 receptor tyrosine kinases [PDF]

open access: yes, 2016
The epidermal growth factor receptor (EGFR)/ErbB family of receptor tyrosine kinases includes oncogenes important in the progression of breast and other cancers, and they are targets for many drug development strategies.
Bose, Ron   +5 more
core   +2 more sources

The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer [PDF]

open access: gold, 2023
Woong Ki Park   +6 more
openalex   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

open access: yesAdvanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He   +17 more
wiley   +1 more source

NRG1 Fusions in NSCLC: Being eNRGy Conscious

open access: yesLung Cancer: Targets and Therapy
Brinda Gupta, Laura Gosa Barrett, Stephen V Liu Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USACorrespondence: Stephen V Liu, Georgetown University, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington,
Gupta B, Gosa Barrett L, Liu SV
doaj  

EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides

open access: yesRadiology and Oncology, 2015
Background. There is limited effect of tyrosine kinase inhibitors or “naked” antibodies binding EGFR or HER2 for therapy of metastasized urinary bladder cancer and these methods are therefore not routinely used.
Carlsson Jörgen   +4 more
doaj   +1 more source

A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT [PDF]

open access: yes, 2016
Targeted cancer therapy aims to disrupt aberrant cellular signalling pathways. Biomarkers are surrogates of pathway state, but there is limited success in translating candidate biomarkers to clinical practice due to the intrinsic complexity of pathway ...
Boiko, Andrei   +6 more
core   +3 more sources

Development of Endogenous Protein Probes for Characterizing Surface Proteins and Cellular Interactors of Extracellular Vesicles

open access: yesAdvanced Science, EarlyView.
The proximity labeling enzyme APEX2 is displayed on extracellular vesicle (EV) surfaces via genetic fusion with EV‐sorting scaffolds, enabling in situ biotinylation of native surface proteins, adsorbed corona components, and interacting cellular proteins.
Wenyi Zheng   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy